Brian T. Hill

19.8k total citations
225 papers, 2.7k citations indexed

About

Brian T. Hill is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Brian T. Hill has authored 225 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Oncology, 102 papers in Pathology and Forensic Medicine and 86 papers in Genetics. Recurrent topics in Brian T. Hill's work include Lymphoma Diagnosis and Treatment (102 papers), Chronic Lymphocytic Leukemia Research (81 papers) and CAR-T cell therapy research (65 papers). Brian T. Hill is often cited by papers focused on Lymphoma Diagnosis and Treatment (102 papers), Chronic Lymphocytic Leukemia Research (81 papers) and CAR-T cell therapy research (65 papers). Brian T. Hill collaborates with scholars based in United States, Canada and India. Brian T. Hill's co-authors include Alexandru Almasan, Eric D. Hsi, Juraj Bodo, Mitchell R. Smith, Suparna Mazumder, Gaurav S. Choudhary, Sayer Al-harbi, Isha Kapoor, Robert M. Dean and Matt Kalaycio and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Brian T. Hill

209 papers receiving 2.7k citations

Peers

Countries citing papers authored by Brian T. Hill

Since Specialization

Citations

This map shows the geographic impact of Brian T. Hill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian T. Hill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian T. Hill more than expected).

Fields of papers citing papers by Brian T. Hill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian T. Hill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian T. Hill. The network helps show where Brian T. Hill may publish in the future.

Co-authorship network of co-authors of Brian T. Hill

This figure shows the co-authorship network connecting the top 25 collaborators of Brian T. Hill. A scholar is included among the top collaborators of Brian T. Hill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian T. Hill. Brian T. Hill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia 2025 ·PubMed ·Matthew S. Davids, Saad S. Kenderian, Ian W. Flinn, Brian T. Hill, Michael B. Maris, Paolo Ghia, Michael Byrne, Nancy L. Bartlett, John M. Pagel, Yan Zheng, (unknown), Wangshu Zhang, (unknown), Javier Pinilla‐Ibarz	2
2	Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma. 2024 ·Journal of Clinical Oncology ·Yucai Wang, Melissa C. Larson, Anita Kumar, Brian T. Hill, David A. Bond, Brad S. Kahl, Alexey V. Danilov, Reid W. Merryman, Natalie S. Grover, Aung M. Tun, Sabarish Ayyappan, Georgios Pongas, Craig A. Portell, Javier Muñoz, Patrick M. Reagan, Muhamad Alhaj Moustafa, Priyanka A. Pophali, Irl Brian Greenwell, Jonathon B. Cohen, Peter Martin	1
3	The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma 2023 ·Bone Marrow Transplantation ·Gabriel Aleixo, Wei Wei, Po‐Hao Chen, Namita Gandhi, Faiz Anwer, Robert M. Dean, Betty K. Hamilton, Brian T. Hill, Deepa Jagadeesh, Jack Khouri, Brad Pohlman, Ronald Sobecks, Allison Winter, Paolo F. Caimi, Navneet S. Majhail	2
4	Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy 2022 ·Blood Advances ·(unknown), Courtney E. Hershberger, (unknown), Agrima Mian, (unknown), (unknown), Daniel M. Rotroff, Brian T. Hill, Neetu Gupta	3
5	Clinical Characteristics and Survival Outcomes of Primary Effusion Lymphoma: A National Cancer Database Study 2022 ·Clinical Lymphoma Myeloma & Leukemia ·Firas Baidoun, Muhamad Alhaj Moustafa, Han W. Tun, Brian T. Hill	9
6	Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective 2022 ·Transplantation and Cellular Therapy ·Scott Goldsmith, Armin Ghobadi, John F. DiPersio, Brian T. Hill, (unknown), Tania Jain	5
7	Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoring 2022 ·Journal of Oncology Pharmacy Practice ·(unknown), Theresa Urban, (unknown), Faiz Anwer, Robert M. Dean, Aaron T. Gerds, Betty K. Hamilton, Deepa Jagadeesh, Matt Kalaycio, Jack Khouri, Brad Pohlman, Ronald Sobecks, Allison Winter, Lisa Rybicki, Navneet S. Majhail, Brian T. Hill	1
8	Resource Utilization and Factors Prolonging Hospitalization for Patients with Refractory and Relapsed Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel 2021 ·Transplantation and Cellular Therapy ·Agrima Mian, Wei Wei, Brian T. Hill, Betty K. Hamilton, Brad Pohlman, Deepa Jagadeesh, Faiz Anwer, Matt Kalaycio, Robert M. Dean, Ronald Sobecks, Navneet S. Majhail	2
9	Comparison of the Prognostic Value of Risk Assessment Tools in Allogeneic Hematopoietic Cell Transplantation 2021 ·Transplantation and Cellular Therapy ·(unknown), Lisa Rybicki, (unknown), (unknown), Faiz Anwer, Robert M. Dean, Brian T. Hill, Matt Kalaycio, Jack Khouri, Deepa Jagadeesh, Brad Pohlman, Ronald Sobecks, Allison Winter, Navneet S. Majhail, Betty K. Hamilton	1
10	Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies 2021 ·Cell Death and Disease ·Isha Kapoor, Juraj Bodo, Brian T. Hill, Alexandru Almasan	9
11	A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies 2020 ·Seminars in Hematology ·Brian T. Hill, Deepa Jagadeesh, Brad Pohlman, Robert M. Dean, Neetha Parameswaran, (unknown), Tomas Radivoyevitch, (unknown), (unknown), (unknown), (unknown), Daniel J. Lindner, Mitchell R. Smith, Yogen Saunthararajah	8
12	Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance 2020 ·Cell Death and Disease ·Isha Kapoor, Juraj Bodo, Brian T. Hill, Eric D. Hsi, Alexandru Almasan	172
13	Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis 2019 ·Blood ·Agrima Mian, Wei Wei, Allison Winter, Jack Khouri, Deepa Jagadeesh, Faiz Anwer, Aaron T. Gerds, Robert M. Dean, Ronald Sobecks, Brad Pohlman, Matt Kalaycio, Betty K. Hamilton, Navneet S. Majhail, Brian T. Hill	5
14	The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population 2019 ·Leukemia & lymphoma ·Charlie Zhong, Loren Gragert, Martin Maiers, Brian T. Hill, (unknown), Ketevan Gendzekhadze, David Senitzer, Joo Y. Song, Dennis D. Weisenburger, Leanne Goldstein, Sophia Wang	6
15	Evaluation of Corticosteroids for Engraftment Syndrome (ES) Prophylaxis in Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT) with High-Dose Melphalan (MEL) 2019 ·Biology of Blood and Marrow Transplantation ·(unknown), Theresa Urban, (unknown), (unknown), (unknown), Robert M. Dean, Aaron T. Gerds, Betty K. Hamilton, Brian T. Hill, Deepa Jagadeesh, Matt Kalaycio, Brad Pohlman, Ronald Sobecks, Lisa Rybicki, Navneet S. Majhail	1
16	Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days 2017 ·Journal of Clinical Apheresis ·Jack Khouri, Lisa Rybicki, Navneet S. Majhail, Matt Kalaycio, Edward A. Copelan, Brad Pohlman, Brian T. Hill, Robert M. Dean, Aleksandr Lazaryan, Betty K. Hamilton, Steven Andrèsen, Ronald Sobecks, Brian J. Bolwell, Hien Liu	6
17	Conditional Long-Term Survival Among Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Autologous Hematopoietic Cell Transplantation (AHCT) 2017 ·Blood ·(unknown), Lisa Rybicki, Brian J. Bolwell, Mohamed A. Kharfan‐Dabaja, Robert M. Dean, Betty K. Hamilton, Rabi Hanna, Deepa Jagadeesh, Matt Kalaycio, Hien Liu, Brad Pohlman, Ronald Sobecks, Brian T. Hill, Navneet S. Majhail	1
18	Outcomes in Patients with Enteropathy-Associated T-Cell Lymphoma (EATL) and Hepatosplenic T-Cell Lymphoma (HSTCL): A Population Based Analysis Using the SEER Data 2017 ·Blood ·Dhruvika Mukhija, Tomas Radivoyevitch, Brian T. Hill, Robert M. Dean, Brad Pohlman, Deepa Jagadeesh	1
19	Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia 2016 ·British Journal of Haematology ·Tadeusz Robak, Andrzej Hellmann, Janusz Kłoczko, Javier Loscertales, Ewa Lech‐Marańda, John M. Pagel, Anthony R. Mato, John C. Byrd, Farrukh T. Awan, Holger Hebart, (unknown), Brian T. Hill, Michael Hallek, Amy J. Eisenfeld, Scott Stromatt, Ulrich Jaeger	30
20	Targeting mTORC1–Mediated Metabolic Addiction Overcomes Fludarabine Resistance in Malignant B Cells 2014 ·Molecular Cancer Research ·Arishya Sharma, Allison J. Janocha, Brian T. Hill, Mitchell R. Smith, Serpil C. Erzurum, Alexandru Almasan	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact